Detailed Narrative
FY25: A Year of Milestone Achievements
Piramal Pharma achieved a significant milestone in FY25, surpassing USD 1 billion in annual revenue with a 12% YoY growth rate. This performance was bolstered by the CDMO segment's 15% growth and the India Consumer Healthcare business crossing the ₹1,000 crore revenue mark. Profitability saw a massive jump, with PAT increasing 5x to ₹91 crores, driven by improved operating leverage and a better revenue mix.
CDMO: Innovation Pivot Drives Growth
The CDMO business is increasingly shifting toward innovation-related work, which now accounts for 54% of segment revenue, up from 45% in FY23. On-patent commercial manufacturing revenue grew from $52 million in FY23 to $179 million in FY25. Management highlighted strong demand for differentiated capabilities like Antibody-Drug Conjugates (ADCs), peptides, and sterile injectables, which now represent 49% of CDMO revenue.
FY26: The Inventory Normalization Headwind
Management proactively guided for a 'muted' FY26, expecting only mid-single-digit consolidated revenue growth. This is primarily due to a 'blockbuster' on-patent product customer pausing orders to normalize inventory after a heavy build-up during their launch phase in FY24-25. This temporary slowdown is expected to cause negative operating leverage, pulling EBITDA margins down to the mid-teen level for the year before a projected recovery in FY27.
Strategic US Expansion and Onshoring Readiness
The company announced a $90 million expansion across its Lexington and Riverview sites in the US to capitalize on the growing demand for ADCs and sterile injectables. Management believes they are 'best positioned' to benefit from the BIOSECURE Act and potential trade tariffs, as they already possess a diversified network of facilities in the US and UK. These expansions are expected to come online and contribute meaningfully by FY27.
Complex Hospital Generics: Expanding Beyond the US
The CHG business crossed $300 million in revenue, maintaining dominant market shares in the US for Sevoflurane (44%) and Baclofen (75%). To drive future growth, Piramal is targeting the $400 million Rest of World (RoW) market. Commercial production of Sevoflurane recently commenced at the Digwal facility in India, which will serve as a key driver for market share expansion in non-US geographies over the next 3-5 years.